ImmunityBio, Inc.
IBRX
$2.13
$0.010.47%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,050.02% | 4,383.61% | 10,051.99% | 2,181.35% | 1,181.12% |
| Total Other Revenue | 64.69% | 60.38% | 86.42% | 127.10% | 215.45% |
| Total Revenue | 1,025.95% | 4,227.22% | 10,238.41% | 2,270.58% | 1,218.71% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1,020.89% | 4,212.39% | 10,219.21% | 2,270.58% | 1,218.71% |
| SG&A Expenses | -4.29% | -2.19% | 13.76% | 28.00% | 27.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.36% | -5.13% | -0.19% | -0.84% | 1.36% |
| Operating Income | 27.43% | 20.55% | 9.15% | 4.75% | 0.51% |
| Income Before Tax | 40.69% | 38.59% | 31.93% | 29.16% | -28.16% |
| Income Tax Expenses | 100.00% | 187.50% | -485.00% | -- | -217.65% |
| Earnings from Continuing Operations | 40.69% | 38.58% | 31.96% | 29.15% | -28.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -10.47% | -35.77% | -81.69% | -87.65% | -88.46% |
| Net Income | 40.69% | 38.58% | 31.93% | 29.09% | -28.33% |
| EBIT | 27.43% | 20.55% | 9.15% | 4.75% | 0.51% |
| EBITDA | 28.23% | 21.11% | 9.19% | 4.73% | 0.19% |
| EPS Basic | 52.95% | 50.82% | 47.69% | 46.85% | 17.17% |
| Normalized Basic EPS | 52.87% | 50.74% | 47.55% | 46.70% | 15.83% |
| EPS Diluted | 52.96% | 47.67% | 44.56% | 43.83% | 14.98% |
| Normalized Diluted EPS | 52.87% | 50.79% | 47.59% | 46.74% | 15.86% |
| Average Basic Shares Outstanding | 25.54% | 25.43% | 30.33% | 37.13% | 54.15% |
| Average Diluted Shares Outstanding | 25.49% | 25.56% | 30.48% | 37.30% | 54.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |